Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Selank vs. Tirzepatide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
Selank is distinguished by selank is a tuftsin-derived heptapeptide with small anxiety-comparator studies; it is not an FDA-approved anxiolytic, nootropic, immune therapy, or substitute for established anxiety care; Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Selank is distinguished in the current record by selank is a tuftsin-derived heptapeptide with small anxiety-comparator studies; it is not an FDA-approved anxiolytic, nootropic, immune therapy, or substitute for established anxiety care. Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceTirzepatide
Selank: Early and limited human evidence. Tirzepatide: Mature human evidence.
Regulatory historyTirzepatide
Selank: Not FDA approved; FDA identifies significant compounding safety concerns. Tirzepatide: FDA approved for defined indications.
Mechanistic breadthSelank
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Selank
- Anxiety and neurasthenia
- Benzodiazepine-comparator and add-on research
- Resting-state brain connectivity
- Cytokine and immune biomarkers
Tirzepatide
- Obesity
- Type 2 diabetes
- Cardiometabolic outcomes
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
SelankNot FDA approved; FDA risk flag
Not FDA approved. FDA lists Selank acetate among bulk substances that may present significant safety risks because of aggregation, peptide-related impurities, potential immunogenicity, and inadequate human safety information.
TirzepatideFDA-labeled indications
FDA approved as Mounjaro for type 2 diabetes and Zepbound for defined adult weight-management and OSA indications.
Evidence depthEvidence, not a winner
SelankSmall/older human comparisons
Several small Russian-language anxiety studies, one 52-person acute fMRI study, one limited cytokine report, and substantially broader animal and laboratory research.
TirzepatideMature Phase 3
Multiple large Phase 3 trials, active-comparator studies, 176-week follow-up, a 13,299-participant cardiovascular outcomes trial, and newer 2026 maintenance data.
Weight outcomesEvidence, not a winner
SelankNo controlled evidence
No controlled human evidence for weight loss, appetite control, or body recomposition was located.
TirzepatidePeer-reviewed Phase 3
SURMOUNT-1 peer-reviewed trial: mean change −15.0%, −19.5%, and −20.9% across studied doses versus −3.1% placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
SelankNo controlled evidence
No controlled human evidence for glycaemic control or diabetes outcomes was located.
TirzepatideApproved + Phase 3
Extensive SURPASS program and FDA approval. SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in type 2 diabetes.
Obstructive sleep apnoeaEvidence, not a winner
SelankNo controlled evidence
No controlled human obstructive-sleep-apnoea or sleep-quality evidence was located.
TirzepatideApproved + Phase 3
Two peer-reviewed Phase 3 trials support the FDA-approved Zepbound indication for moderate-to-severe OSA in adults with obesity.
Cardiovascular outcomesEvidence, not a winner
SelankNo outcomes program
No cardiovascular or cerebrovascular outcomes program was located.
TirzepatideCVOT + HFpEF trial
SURPASS-CVOT found tirzepatide noninferior—but not superior—to dulaglutide for major cardiovascular events. In SUMMIT, a separate placebo-controlled HFpEF-and-obesity population had fewer composite cardiovascular-death or worsening-heart-failure events; that finding is population-specific.
Administration and handlingEvidence, not a winner
SelankHistorical intranasal studies
Historical human reports generally used intranasal products. No FDA-approved dose, route, cycle, reconstitution process, or storage instruction exists.
TirzepatideOfficial FDA label
FDA labels provide product-specific once-weekly subcutaneous dosing and handling. Approved presentations are solutions; no reconstitution is required.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Reproducible clinical benefit, human pharmacokinetics, product-form differences, interactions, immunogenicity, dependence or withdrawal risk, and long-term safety.
- Long-term individual durability and rare events, plus evidence for uses outside studied and approved populations.
Community Intelligence
Emerging patterns, clearly separated from evidence
Selank
No community experiences yetBe the first account holder to contribute.
Tirzepatide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.